Telix Pharmaceuticals Ltd — Director's Dealing 2026

Jun 1, 2026

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Telix Pharmaceuticals Limited
ABN	85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maria Rivas
Date of last notice	14 May 2026 (Appendix 3X)

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)
Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	26 May 2026
No. of securities held prior to change	NIL
Class	Share Appreciation Rights (SARs)
Number acquired	21,597 Share Appreciation Rights
Number disposed

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

---

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	The SARs were allocated to Dr Rivas following shareholder approval at the Company's Annual General Meeting on 21 May 2026. No cash payment is made for the allocation. The notional exercise price is US$9.47
No. of securities held after change	21,597 SARs
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of SARs under Equity Incentive Plan of Telix on the terms and conditions set out in the Explanatory Notes to Item 8 in the Notice of 2026 AGM.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

3 – ${}^{+}$ Closed period Part

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No

• See chapter 19 for defined terms.

01/01/2011

---

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.
  01/01/2011